Total Pageviews

Monday, 12 September 2016

Madu tiruan banjir di Pasaran


Malam ini, 12 September 2016 bersamaan dengan Hari Raya pertama Aidil Adha 2016, ku menonton siaran majalah 3 pada pukul 9.30 hingga 10.00 malam. Ku berasa amat kecewa dengan pendedahan majalah 3 iaitu dari beberapa orang Profesor Universiti Malaysia Terengganu (UMT) yang mendedahkan terdapat banyak madu tiruan dijual di pasaran iaitu mungkin menjangkau 80-90% . Madu tiruan atau madu tidak asli atau madu sintetik dibuat oleh bukan calang calang orang!!! Individu yang berjaya membuat madu sintetik ini mempunyai latar belakang food chemistry dan juga food engineering yang tinggi !!!  Sepatutnya setiap botol madu yang dijual mesti diwajibkan label nama pengeluar, alamat pengeluar, kandungan dan tarikh luput.

Yang sedihnya… kenapa kita tidak mendapat pembelaan yang sewajarnya?

Kenapa masih membiarkan pengusaha madu tiruan berleluasa bergerak bebas menjual madu tiruan yang berpotensi memudaratkan kita sebagai pengguna?

Dari Majalah Tiga malam ini juga dapat dibuktikan bahawa kepercayaan orang ramai bahawasanya madu asli tidak mudah larut dalam air adalah tidak berasas kerana madu asli boleh larut dalam air. Madu asli juga boleh menyerap lebih pantas dari madu tiruan ke dalam kertas.  Ujian terbakar juga adalah meleset.

Seperti disarankan oleh UMT, melalui perbandingan graf, kita memerlukan alat High Performance Liquid Chromatography bagi melihat kehadiran banyak antioksidan dalam madu asli manakala tiada kehadiran antioksidan dilihat dalam madu tiruan!

Kami juga tiada kemudahan mikroskop bagi melihat debunga sebagai kontaminan Normal ada hadir dalam madu asli dimana ia tiada dalam madu sintetik!

Akhir kata pesanan Majalah 3 adalah hanya Jauhari mengenal manikam tetapi berapa kerat Rakyat Malaysia yang boleh membezakan antara madu tiruan dan madu asli hanya dengan melihat dengan pandangan mata tanpa bantuan analisa alat alat canggih seperti HPLC, GC dsbnya?

Adakah kita sanggup melihat semakin ramai antara kita yang mendapat sakit buah pinggang akibat memakan bahan kimia sintetik dalam madu tiruan yang banyak dijual di pasaran?

Wednesday, 7 September 2016

Nyamuk pembawa penyakit


1.   Nyamuk pembawa virus denggi (Virus denggi ujud dalam 4 jenis serotypes iaitu Dens 1, Dens 2, Dens 3 dan Dens 4 ) dan punca penyebab penyakit demam denggi: Nyamuk ini juga boleh membawa Virus Zika dan menyebabkan otak kecil (microcephaly) di kalangan bayi baru lahir
a.     Aedes Albopictus
b.     Aedes Aegypti

2.   Nyamuk pembawa plasmodium (Ada 5 jenis plasmodium iaitu Knowlesi, Vivax, Malariae, Ovale & Falciparum ) dan menjadi punca penyebab penyakit Malaria: Jangkitan dengan Plasmodium Falciparum adalah yg paling bahaya di mana kadar kematian adalah paling tinggi di kalangan 5 jenis parasit/plasmodium 
a.     Nyamuk Anopheles Manculatus
b.     Nyamuk Anopheles Subpictus

3.  Nyamuk pembawa virus J E dan punca penyebab penyakit Japanese Encephalitis :
a.     Nyamuk Culex Tritaeniarynchus
b.     Nyamuk Culex Gelidus
c.      Nyamuk Culex Vishnuii
d.     Nyamuk Culex Pseudovishnuii
e.     Nyamuk Culex Sitiens

4.     Nyamuk pembawa parasit Filaria dan punca penyebab penyakit Filariasis (Elephantiasis):
a.     Nyamuk Mansonia Uniformis





Sunday, 4 September 2016

NanoKnife Lawan Kanser



NanoKnife® provides a minimally invasive option for patients with inoperable or difficult-to-reach tumors, including tumors located near critical structures and major blood vessels in the body. Instead of using extreme heat or cold, which could damage normal adjacent tissues, the NanoKnife System uses electrical currents to destroy cancerous tumors.
Potential benefits of NanoKnife include:
No open incisions
Less damage to healthy tissue
Minimal postoperative pain
Fewer side effects
Short hospital stay
Quick post-operative recovery
Ability to repeat the procedure if new tumors develop

How it works
Instead of using microwave energy, extreme heat or extreme cold, the NanoKnife System uses electrical currents to treat tumors.
While the patient is under general anesthesia, the interventional radiologist carefully guides up to six thin needles (electrodes) into the patient’s body and strategically places them around the tumor. Then, the NanoKnife System sends electrical pulses or currents between each set of needles to puncture permanent nanometer-sized holes into the tumor. This process, called irreversible electroporation (IRE), causes the cancer cells to be unbalanced and triggers a cell “suicide,” thereby destroying the tumor.
The electrical pulses are contained between the electrodes, minimizing damage to surrounding healthy cell tissue, blood vessels and other important structures. After the tumor is destroyed, the body naturally rids itself of the dead cells, which are replaced with healthy cells.
The procedure lasts from two to four hours and is performed on an outpatient basis. The patient is also given antibiotics before and after the procedure to prevent infection.
NanoKnife may be a treatment option for patients who are not candidates for conventional treatments or if other treatments were not effective. Patients with a cardiac pacemaker, abnormal heartbeat or nerve stimulators are not eligible for this procedure.



Nanoknife Ablation Doubles Survival in Pancreatic Cancer





Irreversible electroporation (IRE) — a tissue ablation technique — appears to double median survival compared with historical controls for patients with locally advanced pancreatic cancer (LAPC), according to data extracted from six surgical centers in the United States. The results were published in the September issue of the Annals of Surgery.
"The appropriate and precise use of IRE in appropriately selected patients with locally advanced pancreatic cancer can result in a median overall survival close to 24 months, which is nearly double the survival rate with the best new chemotherapy and chemoradiotherapy," the investigators write in their discussion.
"This study demonstrates that IRE, in conjunction with standard of care, may substantially prolong the survival rates of patients with locally advanced pancreatic cancer," lead author Robert C. G. Martin II, MD, PhD, director of surgical oncology at the University of Louisville, Kentucky, said in a statement.
"While additional research is needed, ablation may represent an addition to the current standard of care for stage 3 pancreatic cancer patients whose only treatment options until now have been chemotherapy or a combination of chemoradiation therapy," he added.
IRE is a novel, nonthermal, tissue-ablation modality that delivers microsecond pulses of direct current to create permanent defects in cell membranes of targeted tissues and spares other tissues and connective tissue in blood vessels. In this study, IRE was delivered by the Nanoknife system (AngioDynamics).
The six surgical centers that participated in the study included the University of Louisville, the Cleveland Clinic, the Henry Ford Hospital in Detroit, the Piedmont Hospital in Atlanta, the Swedish Medical Center in Denver, and the Cancer Treatment Centers of America in Atlanta.
"This report of our 200-patient review is the single largest evaluation to date and further confirms the smaller series that have been published with the use of this treatment in patients with pancreatic adenocarcinoma," Dr Martin and colleagues write in their discussion.
Study Details
This was a registry study. Clinical data on patients treated for LAPC were retrieved from an institutional review board–approved, prospectively maintained soft tissue ablation registry.
Two hundred patients with confirmed LAPC first received induction therapy (chemotherapy, chemoradiation, or both) per institution protocol. Approximately 1 month after completion of induction treatment, patients were restaged with repeat triple-phase CT scan and serum tumor markers.
The decision to perform IRE with the Nanoknife system was made in appropriate patients. Patients' comorbidities, previous therapy, and intraoperative preresection margin assessment were used to determine whether surgical resection was possible; in these patients, IRE was used for tumor margin attenuation (n = 50).


"IRE was not used when an R2 resection could occur; and those patients underwent an IRE without resection," Dr Martin and investigators state. LAPC with IRE (in situ) was undertaken in 150 patients.

Terapi T Cell melawan kanser




Scientists report "unprecedented" success using T-cells to treat cancer


15 02 2016



An international team of researchers has seen "extraordinary" results using patients' own immune cells to fight cancer. In one trial, 94 percent of patients with acute lymphoblastic leukaemia saw their symptoms disappear entirely.

For patients with other types of blood cancer, response rates have been above 80 percent, and more than half have experienced complete remission, cancer researchers reported at the American Association for the Advancement for Science conference over the weekend.

The new T-cell treatment is a type of immunotherapy, and it involves taking a patient's own immune cells - specifically, white blood cells called T-cells - and reprogramming them to attack tumours. It's sort of like creating a tailor-made vaccine response against cancer.
Scientists have been working on immunotherapy for decades, but have only recently started testing this new T-cell therapy in humans. Due to the experimental nature of the research, for now, the trials have been limited to patients who are no longer responding to other treatments, and only have a few months to live.
But results are finally beginning to emerge, and, if the conference presentation is anything to go by, the treatment has incredible potential for patients with unresponsive tumours.
"This is unprecedented in medicine, to be honest, to get response rates in this range in these very advanced patients," Stanley Riddell, an immunotherapy researcher at Fred Hutchinson Cancer Research Centre in Seattle, explained at the conference, as The Guardian reports.
"In the laboratory and in clinical trials, we are seeing dramatic responses in patients with tumours that are resistant to conventional high-dose chemotherapy," he added in a press statement. "The merging of gene therapy, synthetic biology and cell biology is providing new treatment options for patients with refractory malignancies and represents a novel class of therapeutics with the potential to transform cancer care."
T-cells are white blood cells that are responsible for detecting foreign or abnormal cells - including cancerous ones - and then latching onto them to tell the rest of the immune system that they need to be attacked.
Unfortunately, this immune response is often not quick or aggressive enough to get rid of fast-growing tumours. Over time, T-cells become exhausted, and some tumour types learn to evade them, allowing them to dodge the immune system altogether. 
This is where immunotherapy comes in - to put the system into overdrive, scientists perform what's known as adoptive T-cell transfer. This means they first extract patients' T-cells from their blood, and, using gene transfer, introduce receptors that will aggressively target a specific cancer cell. Once back inside the body, these newly engineered T-cells regenerate to create an army of immune cells prepped to take down tumours.
Using this technique, Riddell reports that he and his colleagues have seen"sustained regression" in previously terminal cases of acute lymphoblastic leukaemia, Non-Hodgkin lymphoma, and chronic lymphocytic leukaemia.
The results have been submitted for publication, and are now undergoing peer-review, which means we can't get too excited about them just yet, and there aren't huge amount of details to go off - but we do know that the aforementioned trial with the 94 percent success rate involved 35 patients, and the blood cancer study that achieved greater than 80 percent response rates involved 40 participants.
To be clear, as promising as these results are, this therapy is never likely to be a potential 'cure' for cancer, and will most likely be reserved for the most extreme cases. This is mainly because the potential side effects are severe - during the trials, 20 patients suffered symptoms of fever, hypotension, and neurotoxicity due to something called cytokine release syndrome, and two patients died.
"Much like chemotherapy and radiotherapy, it’s not going to be a save-all," said Riddell. "These are in patients that have failed everything. Most of the patients in our trial would be projected to have two to five months to live ... [But] I think immunotherapy has finally made it to a pillar of cancer therapy."
Italian cancer researcher Chiara Bonini also spoke at the conference, and was more hopeful about the therapy, as The Guardian reports.
"This is really a revolution," she said. "T-cells are a living drug, and in particular they have the potential to persist in our body for our whole lives ... Imagine translating this to cancer immunotherapy, to have memory T-cells that remember the cancer and are ready for it when it comes back."
Riddell's lab is now working on applying the T-cell therapy to a wider range of cancers - not just blood cancers - and is trying to make engineered T-cells safer and easier to design. The team also wants to track how long patients remain in remission following the treatment before progressing with broader trials.
We'll need to wait for peer-reviewed results before we know exactly how excited we should get about T-cell therapy, so watch this space. 




Rawatan Alternatif





PENAMPILANNYA bersahaja, memakai topi koboi, dia memberi ceramah tentang kesihatan yang diselangi dengan unsur jenaka. Pasti ramai yang tidak menyangka lelaki ini sebenarnya pakar perubatan holistik.

Pemilik sebuah syarikat dinamik yang mempunyai rangkaian produk kesihatan, Jobless Millionaires International (JMI) ini mungkin sudah mencapai segala yang diimpikannya. Beliau mempunyai kerjaya yang bagus sebagai doktor perubatan, keluarga yang bahagia bahkan mampu memandu kereta mewah sendiri. Namun, semua itu bukanlah noktah perjuangannya kerana dia mahu mendidik dan membantu masyarakat tentang pengertian kesihatan sebenar.

Prof. Datuk Seri Dr. Syed Putra Meir bukanlah nama asing dalam bidang holistik. Beliau merupakan Pakar Holistik Pemakanan dan Perubatan Orthomolekul.

Dr. Syed mendapat pengiktirafan daripada Kementerian Kesihatan Republik Indonesia dan diiktiraf sebagai pakar perubatan dalam bidang rawatan alternatif. Kini beliau fokus dalam bidang rawatan alternatif penyakit kanser kronik dan menjadi ahli Persatuan Pengguna Islam Malaysia.

Dr. Syed memberitahu, dia memperolehi ilmu pengetahuan tentang bidang ini di Hospital The Oasis of Hope, Tijuana, Mexico.

“Di sana saya mempelajari cara merawat penyakit kanser melalui kaedah perubatan altenatif orthomolekul,” katanya. Perjuangannya tidak hanya terhenti di situ sahaja, beliau kemudian menubuhkan JMI iaitu kumpulan anak syarikat Vision B Seventeen Sdn. Bhd. yang berpangkalan di Malaysia. Tambah Dr. Syed, visi dan matlamat syarikatnya adalah untuk menyediakan akses kepada rawatan yang berkualiti kepada semua masyarakat terutama untuk penyakit abad ke-21 yang menjadi igauan hidup masyarakat zaman moden ini.

Ditanya pilihan bidangnya iaitu penyakit kanser, Dr. Syed yakin bahawa kanser bukanlah hukuman mati dan boleh dirawat.

“Tiada sebarang keraguan dalam minda saya tentang kenyataan ini,” katanya ringkas.
Dr. Syed sudah pun mengamalkan kaedah rawatan ini sejak dua dekad lalu. Beliau mengakui pada mulanya kaedah rawatan alternatif kurang mendapat sambutan dan kurang diterima.

“Banyak keraguan dan syak wasangka yang timbul dalam kalangan orang ramai waktu itu. Namun, perubatan moden pun ada batasnya. Kebanyakan pesakit kanser datang dan meminta rawatan daripada saya apabila keadaan mereka sudah kronik. Majoritinya ialah tahap empat dan datang mendapatkan rawatan daripada saya sebagai pilihan terakhir. Bagi saya, penyakit ini boleh dikawal dan ditangani. Lama-kelamaan ramai yang boleh menerima rawatan alternatif kerana keputusan positif pesakit,” ujarnya.

Dalam pada itu, Dr. Syed mengakui, sukar untuk mencari keseimbangan antara kerjaya dan keluarga tetapi apabila kita melakukan sesuatu perkara dengan ikhlas dan jujur, pasti kita akan dapat mengatasi segala cabaran dan dugaan. Katanya, dia amat bertuah kerana keluarganya memahami kepentingan kerjayanya dan sentiasa membantu dalam segala aspek.

“Saya amat berbesar hati untuk berkongsi masa dengan pesakit kerana menyedari bahawa saya ialah peluang terakhir bagi mereka. Saya sentiasa meletakkan kebajikan pesakit sebagai kepentingan utama dan amat berterima kasih kepada kepercayaan dan kesabaran serta sikap toleransi mereka kepada saya,” katanya.

Sementara itu, sebagai Pengerusi Eksekutif JMI, Dr. Syed akan memastikan produk keluaran syarikatnya berkualiti dan selamat. Oleh itu, semua produk JMI berasal dari formula Amerika Syarikat yang dikilangkan di bawah standard kawalan kualiti yang ketat.

“JMI menjual produk yang terbukti berkesan dengan harga berpatutan. Orang ramai yang ingin mengetahui lebih lanjut tentang JMI, boleh melayari www.joblessmillionaires.com atau hubungi 0320356889,” katanya.



Vit C Lawan ZIKA






(NaturalHealth365) Ebola virus infection typically results in a rapidly evolving clinical syndrome that results in death in a week or less in a majority of the cases documented in areas of Africa, even though the incubation period leading to clinical disease can last up to three weeks. However, probably the main factor in determining whether a fatal outcome is quickly seen depends on the immunocompetenceand nutritional status of the infected individual.
Although the Ebola “panic” initiated by the Centers for Disease Control and Prevention (CDC) and other governmental health organizations in 2014 had many people wondering if they would be lucky enough to avoid infection and “inevitable” death, it has been well-documented that individuals can have Ebola antibodies circulating in their blood, indicating they encountered or contracted the virus but had a completely protective immune response. This was the case in 11 individuals working with Ebola patients in Central Africa who were tested.

Infections rapidly leading to death seen in seemingly well-nourished individuals can be avoided

Robert Rowen, MD demonstrated that a protocol of ozone, vitamin C, and a supplement containing multiple antioxidants is highly effective in resolving (curing) clinically symptomatic, documented cases of Ebola virus infection in Sierra Leone. The ozone was administered by direct intravenous gas administration, rectal ozone gas insufflation, and the ingestion of ozonated water. A daily dose of four to eight grams of vitamin C was given, along with two tablets daily of a supplement containing thiamin, riboflavin, selenium, N-acetyl cysteine, glutathione, lipoic acid, and an additional small amount of vitamin C.
Chikungunya virus produces a syndrome that is truly debilitating, with severe joint pains that often persist for months and even years. Indeed, some individuals appear to never completely recover from it.
In Puerto Rico, in the middle of a very sizable Chikungunya epidemic, a physician treated 56 patients with a single infusion of vitamin C (ascorbic acid), dosage ranging between 25 and 50 grams, followed by a single infusion of hydrogen peroxide (3 cc of a 3% solution in 100 cc of normal saline). 60% of the patients reported a dramatic reduction in pain immediatelypost-infusion, and 5 of the patients (9%) reported complete elimination of Chikungunya virus-related pain. This was the first report in the peer-reviewed medical literature that applied infusions of both ascorbic acid and hydrogen peroxide in a treatment regimen. A 20 to 25% recurrence/relapse occurred after this initial approach, and a complete resolution of the virus was typically rendered with three additional infusions of vitamin C (Marcial-
Vega et al., 2015).

What’s really behind the spread of most viral infections?

Currently, treating viral syndromes such as Chikungunya involves the administration of analgesics such as acetaminophen as the primary therapy, relying completely on the immunocompetence of the infected individual to eventually defeat the virus and allow recovery. Indeed, there were so many Chikungunya viral infections in Cali, Colombia in 2015 that a “shortage” of acetaminophen developed in hospitals and clinics throughout the city.
Furthermore, it also needs to be emphasized that very many cases of Chikungunya virus were transmitted in families in Cali without anyone being bitten by a mosquito, even though it is asserted that this is the only way one can acquire this viral infection. At least with Chikungunya, and possibly with the Zika and Dengue fever viruses as well, it would appear that mosquitos help to spread the infection and amplify its presence in a community but are not absolutely required for the infections to be contracted. Certainly, Ebola virus does not require the mosquito for transmission.

Dengue fever successfully eliminated with vitamin C

Dengue fever appears to be similarly susceptible to vitamin C therapy. I treated one case of hemorrhagic Dengue fever (blood in the urine) in a 15 year-old girl in Colombia, South America with part of my own personal supplement supplies that I had with me at the time. Specifically, I gave her about 10 packets of liposome-encapsulated vitamin C (1,000 mg per packet) to be taken orally over the following 48 hours. She was completely recovered by the time she had taken the last packet.
Liposome-encapsulated vitamin C, properly-dosed, can be enormously effective in acute viral and bacterial infections. However, it is important to take a vitamin C formulation that is truly liposome-encapsulated for optimal intracellular antioxidant impact.

What should we do with the Zika virus?

The current bogeyman that could once again ending up terrorizing the United States and other countries around the world is the Zika virus. Since “modern” medicine still refuses to acknowledge the many ways in which viral syndromes can be quickly and efficiently cured the vast majority of the time, both doctors and patients alike feel their fate lies in the hands of an arbitrary infection until an “effective vaccine” can be produced.
Even if fast-tracked, such a vaccine should take a good two years to be developed and ready for administration. And there is certainly no guarantee that such a vaccine would be either effective or free of significant (negative) side effects.
The Zika virus is also generating increased concern by its reported relationship to birth defects, particularly microcephaly, meaning a small head and small brain have developed during the pregnancy. While there is serious doubt that this virus is in fact wedded to this particular birth defect, the scare has already been widely circulated, and it is unlikely that pregnant women or women seeking to become pregnant will be put completely at ease by any information to the contrary.

When will ‘modern’ medicine wake up to the reality of successful treatment options?

Unlike Ebola, Chikungunya, and Dengue, there are not yet any reported cases of Zika virus infection being treated with ozone, vitamin C, or hydrogen peroxide. However, it would completely defy scientific logic to think that Zika would not be readily responsive to any or all of these anti-viral therapies. All viruses to date that have been treated in the test tube or in the infected patient have responded in a similar positive fashion.
What these therapies share is an oxidant, or pro-oxidant, impact on the infecting agent. When something, either a biomolecule or a pathogenic virus, is sufficiently oxidized, it is rendered inactive. When enough oxidation is inflicted, such a virus can frankly rupture and be excreted and/or assimilated to a limited degree in other biomolecules in the body. For all intents and purposes, this means the virus has been “killed,” although some purists do not like such an assertion since a virus is not considered to have a life force by itself, but only when it takes over and “infects” a living cell.

What makes vitamin C so special?

While it has been clearly established (although remaining completely unappreciated) that oxidative therapies (such as ozone, hydrogen peroxide, hyperbaric oxygen therapy, and ultraviolet blood irradiation, to name the most commonly utilized) can rapidly resolve viral (and many bacterial) infections, vitamin C is uniquely positioned to offer so much more to the infected patient than any other of the oxidative therapies.
While the vitamin C molecule is only antioxidant in nature, capably of only donating electrons (versus oxidative therapies, which oxidize, or take electrons away), it is capable of giving its electrons to molecules that can pass them along to hydrogen peroxide inside the pathogen or infected cell, generating the most potent pro-oxidant molecule of all, the hydroxyl radical (Fenton reaction). Also, by mechanisms not yet clearly defined, high enough doses of vitamin C also appear to directly promote the production of hydrogen peroxide in the extracellular space, which would rapidly kill or neutralize any pathogens in those areas of the body as well.
But what vitamin C offers that none of the other oxidant therapies offer is that it is also the body’s most widespread and vital nutrient. While the other oxidants are highly effective in killing pathogens, they offer nothing to help rebuild the normal tissue and connective structures that the infection has compromised.

What do all of these viruses have in common?

Indeed, all of the viruses discussed in this article quickly and rapidly consume local and systemic vitamin C stores, resulting very effectively in a clinical picture of acute scurvy. Small blood vessels are especially affected by this vitamin C depletion, and the loss of vitamin C-dependent connective tissue integrity in these small vessels is the reason that advanced infections with these viruses results in hemorrhage in various areas of the body.
However, there is certainly no need to use just vitamin C and nothing else, although it would often take care of any acute viral infection as a monotherapy. In any given patient, you want to get on top of the infection as quickly and completely as possibly, since the main concern is intervening too late to deal with a very high pathogen titer and advanced tissue and organ damage.
Therefore, it is most appropriate to treat an acute infection with whatever oxidant therapies are available, while also dosing vitamin C at optimal levels. And when someone still isn’t responding optimally, consider proceeding directly to dosing vitamin C at high levels in at least four different forms, as outlined in the ‘Multi-C Protocol.’
Very few viral and bacterial infections, except when already very advanced with multi-organ failure present or imminent, will fail to respond to this approach. Instead, a complete cure can routinely be anticipated. Much of the reason for this is that there is nothing more critical in restoring and sustaining immune system strength and tissue integrity than vitamin C.
The other pro-oxidant therapies do not provide this enormous advantage (Levy, 2002).
About the Author: Thomas E. Levy, MD, JD is a board-certified internist and cardiologist. He is also bar-certified for the practice of law. He has written 10 books now, generally concentrating on the importance of eliminating toxins while bolstering antioxidant defenses in the body, with particular focus on vitamin C. His website is PeakEnergy.com, which also contains many articles addressing a variety of medical topics. His latest book, The Toxic Tooth: How a root canal could be making you sick, co-authored with Robert Kulacz, DDS, is now available at MedFoxPub.com, along with the rest of his books.